Adults 18 to 99, any sex, with Relapsed or Refractory Multiple Myeloma. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Overall Response Rate (ORR) As Assessed by the Independent Review Committee (IRC)Primary· From day 1 cycle 1 until the primary analysis (PA) data cutoff (DCO); the mean duration of KPd treatment as of the DCO was 42.0 weeks
Overall response was defined as the best overall confirmed response of: Complete response (CR): Negative immunofixation on serum and urine, soft tissue plasmacytomas disappearance, \< 5% plasma cells in bone marrow (BM). Stringent CR (sCR): CR and normal serum free light chain ratio and no clonal cells in BM. Very Good Partial Response (VGPR): Serum and urine M-protein detectable by immunofixation or ≥ 90% reduction in serum M-protein (urine M-protein level \< 100 mg/24-h). PR: ≥ 50% reduction of serum M-protein and 24-h urinary M-protein by ≥ 90% or to \< 200 mg/24-h. Assessment was by IRC pe
Group
Value
95% CI
Carfilzomib With Pomalidomide and Dexamethasone (KPd)
57.7
45.4 – 69.3
Percentage of Participants With a Minimal Residual Disease Negative Complete Response (MRD[-]CR) as Assessed by the IRCSecondary· Day 1 cycle 1 to month 12 (8 to 13 month window)
The MRD\[-\]CR rate was defined as the percentage of participants who reached MRD\[-\]CR at the 12 month landmark (8- to 13-month window). MRD\[-\]CR was defined as the achievement of CR (including sCR or better) per IMWG-URC by IRC assessment and MRD\[-\] status at a sensitivity of 10\^-5 using next-generation sequencing based method in the bone marrow. The 90% CIs were estimated using the Clopper-Pearson method (1994).
Group
Value
95% CI
Carfilzomib With Pomalidomide and Dexamethasone (KPd)
3.8
0.7 – 11.6
Number of Participants With Treatment-emergent Adverse Events (TEAEs)Secondary· From the first dose of any study treatment until the end of study or 30 days after the last dose of any study treatment, whichever occured earlier; Median (min, max) was 8.5 (1.0, 46.6) months
TEAEs were defined as events with onset on or after the administration of the first dose of any study treatment and within the end of study, or 30 days after the last dose of any study treatment, whichever one was earlier, excluding events reported after end of study date.
Group
Value
95% CI
Carfilzomib With Pomalidomide and Dexamethasone (KPd)
50
Number of Participants Achieving MRD[-] ResponseSecondary· From day 1 cycle 1 until the end of study (EOS); the mean duration of KPd treatment as of the EOS was 55.3 weeks
MRD\[-\] response was defined as achievement of MRD\[-\] status using next generation sequencing (NGS) based method in the bone marrow at any time.
Group
Value
95% CI
Carfilzomib With Pomalidomide and Dexamethasone (KPd)
5
Number of Participants With Sustained MRD[-]CR for at Least 12 Months as Assessed by the IRCSecondary· Day 1 cycle 1 to month 12 (8 to 13 month window)
MRD\[-\]CR at the 12 months landmark was defined as achievement of CR (including sCR or better) per IMWG-URC by IRC and MRD\[-\] status at a sensitivity of 10\^-5 using NGS based method in the bone marrow at the 12 months landmark (from 8 months to 13 months window). Maintaining MRD\[-\]CR for at least 12 months (- 4 weeks) was considered as sustained.
Group
Value
95% CI
Carfilzomib With Pomalidomide and Dexamethasone (KPd)
0
Number of Participants With Sustained MRD[-]CR at Month 24 as Assessed by the IRCSecondary· Day 1 cycle 1 to month 26 (19 to 26 month window)
Sustained MRD\[-\]CR at 24 months included participants that maintained MRD\[-\]CR for 12 months or more after achieving MRD\[-\]CR status at 12 months.
Group
Value
95% CI
Carfilzomib With Pomalidomide and Dexamethasone (KPd)
0
Kaplan-Meier Estimate of Duration of Response as Assessed by the IRCSecondary· From day 1 cycle 1 until the PA DCO; the mean duration of KPd treatment as of the DCO was 42.0 weeks
Disease response and progression were determined using IMWG-URC. Durations were calculated for responders. Medians and percentiles were estimated using the Kaplan-Meier method. 90% CIs for medians and percentiles were estimated using the method by Klein and Moeschberger (1997) with log-log transformation.
Group
Value
95% CI
Carfilzomib With Pomalidomide and Dexamethasone (KPd)
20.3
9.2 – NA
Time to Response as Assessed by the IRCSecondary· From day 1 cycle 1 until the PA DCO; the mean duration of KPd treatment as of the DCO was 42.0 weeks
Durations were calculated for responders. Time to response was defined as the time from start of any study treatment date to the earliest date when confirmed sCR, CR, very good partial response (VGPR), or partial response (PR) was first achieved.
Group
Value
95% CI
Carfilzomib With Pomalidomide and Dexamethasone (KPd)
1.0
1 – 2
Kaplan-Meier Estimate of Progression Free Survival (PFS) as Assessed by the IRCSecondary· From day 1 cycle 1 until the PA DCO; the mean duration of KPd treatment as of the DCO was 42.0 weeks
PFS was defined as time from start of treatment until progression or death from any cause. Medians and percentiles were estimated using the Kaplan-Meier method by Klein and Moeschberger (1997). 90% CIs for medians were estimated using the method by Klein and Moeschberger (1997) with log-log transformation.
Group
Value
95% CI
Carfilzomib With Pomalidomide and Dexamethasone (KPd)
11.1
6.5 – NA
Kaplan-Meier Estimate of Overall Survival (OS)Secondary· From day 1 cycle 1 until the EOS; the mean duration of KPd treatment was 55.3 weeks.
OS was defined as the time from the start of treatment until death from any cause. Medians and percentiles were estimated using the Kaplan-Meier method. 90% CIs for medians were estimated using the method by Klein and Moeschberger (1997) with log-log transformation.
Group
Value
95% CI
Carfilzomib With Pomalidomide and Dexamethasone (KPd)
17.6
11.2 – 23.5
Number of Participants With Best Overall Confirmed Response of CR or Better as Assessed by the IRCSecondary· From day 1 cycle 1 until the PA DCO; the mean duration of KPd treatment as of the DCO was 42.0 weeks
The number of safety analysis set participants whose best overall response was sCR or CR per IMWG-URC over the duration of the study.
Group
Value
95% CI
Carfilzomib With Pomalidomide and Dexamethasone (KPd)
3
Adverse events — posted to ClinicalTrials.gov
Time frame: All-cause mortality: from enrollment until the end of study or death date, whichever occurs later; Median (min, max) time on study was 15.2 (0.0, 47.0) months. Adverse events: from the first dose of any study treatment until the end of study or 30 days after the last dose of any study treatment, whichever occurs earlier; Median (min, max) was 8.5 (1.0, 46.6) months.
Reporting threshold: 5%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
Carfilzomib With Pomalidomide and Dexamethasone (KPd)
NCT07463807 — Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carf
· Phase 1, PHASE2
· not yet recruiting
NCT06948084 — Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Darat
· Phase 2
· not yet recruiting
NCT06918990 — Treatment of Antibody-Mediated Rejection (ABMR) With CarBel
· Phase 2
· not yet recruiting
NCT07082270 — Selvigaltin With Standard of Care Treatment for the Treatment of Relapsed/Refractory Multiple Myeloma
· Phase 1
· withdrawn
NCT07391657 — A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regi
· Phase 3
· recruiting
Other recruiting trials for Relapsed or Refractory Multiple Myeloma
Currently open trials in the same condition.
NCT07369895 — Clinical Study of O&D-001 Injection in the Treatment of Relapsed or Refractory Multiple Myeloma
· Phase 1
· recruiting
NCT07116616 — A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
· Phase 1, PHASE2
· recruiting
NCT07312188 — A Study of F182112 in the Treatment of Patients With Relapsed or Refractory Multiple Myeloma
· Phase 2
· recruiting
NCT06604715 — A Study of JNJ-87562761 in Participants With Relapsed or Refractory Multiple Myeloma
· Phase 1
· recruiting
NCT06574568 — A Study of YKST02 in Participants With Relapsed or Refractory Multiple Myeloma
· Phase 1
· recruiting
Other Amgen trials
Trials by the same sponsor.
NCT07223190 — A Study Evaluating Subcutaneous Versus Intravenous Blinatumomab in Newly Diagnosed Adults With B-cell Precursor Acute Ly
· Phase 3
· not yet recruiting
NCT07493512 — Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Cancer
· Phase 1
· not yet recruiting
NCT07531095 — Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC)
· Phase 1
· not yet recruiting
NCT06987539 — A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Gen
· Phase 2
· recruiting
NCT05909761 — Observational Safety Study in Women With Neuromyelitis Optica Spectrum Disorder (NMOSD) Exposed to UPLIZNA® During Pregn
· recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Amgen
Last refreshed: 4 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04191616.